Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)
The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Acetylcholinesterase (AChE) is the major enzyme that hydrolyzes acetylcholine, a key neurotransmitter for synaptic transmission, into acetic acid and choline. Mild inhibition of AChE has been shown to have therapeutic relevance in Alzheimer's disease (AD), myasthenia gravis, and glaucoma among others. In contrast, strong inhibition of AChE can lead to cholinergic poisoning. To combat this, AChE reactivators have to be developed to remove the offending AChE inhibitor, restoring acetylcholine levels to normal. Areas covered: This article covers recent advances in the development of acetylcholinesterase modulators, including both inhibitors of acetylcholinesterase for the efforts in development of new chemical entities for treatment of AD, as well as re-activators for resurrection of organophosphate bound acetylcholinesterase. Expert opinion: Over the past three years, research efforts have continued to identify novel small molecules as AChE inhibitors for both CNS and peripheral diseases. The more recent patent activity has focused on three AChE ligand design areas: derivatives of known AChE ligands, natural product based scaffolds and multifunctional ligands, all of which have produced some unique chemical matter with AChE inhibition activities in the mid picomolar to low micromolar ranges. New AChE inhibitors with polypharmacology or dual inhibitory activity have also emerged as highlighted by new AChE inhibitors with dual activity at L-type calcium channels, GSK-3, BACE1 and H3, although most only show low micromolar activity, thus further research is warranted. New small molecule reactivators of organophosphate-inhibited AChE have also been disclosed, which focused on the design of neutral ligands with improved pharmaceutical properties and blood-brain barrier (BBB) penetration. Gratifyingly, some research in this area is moving away from the traditional quaternary pyridinium oximes AChE reactivators, while still employing the necessary reactivation group (oximes). However, selectivity over inhibition of native AChE enzyme, effectiveness of reactivation, broad-spectrum reactivation against multiple organophosphates and reactivation of aged-enzyme continue to be hurdles for this area of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“tau deposits, which affects microtubule stability and likely enhances the toxicity of β-amyloid [21].”
BackgroundA Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Antioxidant and radical scavenging properties of curcumin
Ak, T., & Gülçin, İ. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.003 · Cited by 1,651 · cited 1×
“reduce free radical species and hydrogen peroxide, as well as chelation of biometals [109].”
BackgroundAuto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor
Arrang, J.-M., Garbarg, M., & Schwartz, J.-C. (1983) · Nature · doi:10.1038/302832a0 · Cited by 1,575
Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands
Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,356 · cited 1×
“volumes (727 and 683 Å [3], respectively) due to slightly different amino acid sequences [13].”
BackgroundMolecular and cellular biology of cholinesterases
Massoulié, J., Pezzementi, L., Bon, S., Krejci, E., & Vallette, F.-M. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90040-y · Cited by 1,214 · cited 1×
“Cholinesterase (ChE) is family of enzymes made up of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) that are capable of hydrolyzing neurotransmitter acetylcholine (ACh) into acetic acid and choline [1].”
BackgroundMulti-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101 · cited 1×
“amyloid plaques, which in turn increases the expression of AChE [16,23].”
BackgroundAcetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states
Quinn, D. M. (1987) · Chemical Reviews · doi:10.1021/cr00081a005 · Cited by 1,072 · cited 1×
“tions within the catalytic triad (Figure 2) [10].”
BackgroundNeurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1035 · Cited by 891
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Birnie, K. A., Noel, M., Chambers, C. T., Uman, L. S., & Parker, J. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005179.pub4 · Cited by 755
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Phytochemical dictionary. A handbook of bioactive compounds from plants.
Harborne, J. B., Baxter, H., & Moss, G. P. (1999) · Taylor & Francis eBooks · Cited by 633
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · cited 1×
“However, after 26 weeks treatment of tideglusib, no significant clinical benefit was observed [113].”
BackgroundNachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P.-Y. (2013) · Biochemical Journal · doi:10.1042/bj20130013 · Cited by 478
The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity
Liu, J.-S., Zhu, Y.-L., Yu, C.-M., Zhou, Y.-Z., Han, Y.-Y., Wu, F.-W., & Qi, B.-F. (1986) · Canadian Journal of Chemistry · doi:10.1139/v86-137 · Cited by 473 · cited 1×
“as a dietary supplement for improvement of cognitive function and memory [56].”
BackgroundAcetylcholine, Aging, and Alzheimer's Disease
Muir, J. L. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00431-5 · Cited by 360 · cited 1×
“AD is a form of dementia characterized by a decline in shortterm memory, cerebral atrophy, β-amyloid plaques, and tangles as well as filamentous tau protein deposits [17] [19].”
BackgroundFarlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · cited 1×
“One of the wellrecognized examples of stigmines, rivastigmine, a semisynthetic derivative of physostigmine, was approved for the treatment of mild-to-moderate AD in 2000 and more recently for Parkinson’s disease dementia [61].”
BackgroundSchool-based education programmes for the prevention of child sexual abuse
Walsh, K., Zwi, K., Woolfenden, S., & Shlonsky, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004380.pub3 · Cited by 318
Alvarez, A., Alarcón, R., Opazo, C., Campos, E. O., Muñoz, F. J., Calderón, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., De Mello, F. G., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03213.1998 · Cited by 317 · cited 1×
“More importantly, the AChE–amyloid complexes account for higher neurotoxicity than β-amyloid plaques alone [44].”
BackgroundStructure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution
Greenblatt, H. M., Kryger, G., Lewis, T., Silman, I., & Sussman, J. L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01637-3 · Cited by 310 · cited 1×
“Based on the X-ray structure of Torpedo californica AChE and (–)–galantamine complexes, it was found and suggested that the tertiary amine group could be structurally modified to further improve the ligand’s activity by interacting with both catalytic and peripheral sites [54].”
BackgroundThe histamine H3receptor: an attractive target for the treatment of cognitive disorders
Esbenshade, T. A., Browman, K. E., Bitner, R. S., Strakhova, M., Cowart, M. D., & Brioni, J. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.147 · Cited by 296
Synthesis and Pharmacology of Galantamine
Marco-Contelles, J., do Carmo Carreiras, M., Rodríguez, C., Villarroya, M., & García, A. G. (2006) · Chemical Reviews · doi:10.1021/cr040415t · Cited by 293
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Fernández-Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodríguez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 268 · cited 1×
“lished a series of tacrine–flavonoid hybrids with different orientation and substituents on the 4-oxo-4H-chromene core and tethered with a more flexible alkylenediamine linker as compared to compound 33 [107].”
BackgroundAcetylcholinesterase: How is structure related to function?
Silman, I., & Sussman, J. L. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.035 · Cited by 263
Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., & Bartolomé, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 248
Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240 · cited 1×
“reviews on MTDLs in AD treatment have been well documented by Malawska’s group, as well as Wang and Chen’s group covering reports from early 2000 to 2014 [72,73].”
MethodResearch and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor
Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., & Yamanishi, Y. (2002) · Japanese Journal of Pharmacology · doi:10.1254/jjp.89.7 · Cited by 240 · cited 1×
“Donepezil was the second FDA-approved synthetic AChE inhibitor specifically designed for the treatment of AD, and it was released soon after the failure of tacrine in 1996 [48].”
BackgroundRational Approach To Discover Multipotent Anti-Alzheimer Drugs
Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 226 · cited 1×
“as anti-amyloid aggregation and antioxidant activities [88].”
Muñoz-Ruiz, P., Rubio, L., García-Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 219 · cited 1×
“sively by the Martinez and Rodriguez-Franco groups, and they have independently identified several compounds that displayed the highest potency reported to date for both AChE inhibition and β-amyloid anti-aggregation [75] [77].”
BackgroundTacrine: First Drug Approved for Alzheimer's Disease
Crismon, M. L. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800612 · Cited by 218
Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimer's Disease
Bai, D. L., Tang, X. C., & He, X. C. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003375281 · Cited by 216
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
Jokanovic, M., & Prostran, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788612729 · Cited by 188 · cited 1×
“this P=S bond is rapidly oxidized to the resulting P=O bond, releasing the active AChE inhibitor [33].”
BackgroundFabrichny, I. P., Leone, P., Sulzenbacher, G., Comoletti, D., Miller, M. T., Taylor, P., Bourne, Y., & Marchot, P. (2007) · Neuron · doi:10.1016/j.neuron.2007.11.013 · Cited by 184 · cited 1×
“nesterase (rhAChE) has an ellipsoid shape that is 45 Å by 60 Å by 65 Å and is made up of a 12-stranded central mixed β-sheet enclosed by 14 α-helices [6].”
BackgroundRole of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies
Aarsland, D., Mosimann, U. P., & McKeith, I. G. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704267463 · Cited by 180 · cited 1×
“Patients in clinical studies treated with AChE inhibitors also displayed an improvement of symptoms [29].”
BackgroundInteractions between the amyloid and cholinergic mechanisms in Alzheimer's disease
PAKASKI, M., & KALMAN, J. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.06.005 · Cited by 178 · cited 1×
“AD is a form of dementia characterized by a decline in shortterm memory, cerebral atrophy, β-amyloid plaques, and tangles as well as filamentous tau protein deposits [17] [19].”
BackgroundReview of the acetylcholinesterase inhibitor galanthamine
Sramek, J. J., Frackiewicz, E. J., & Cutler, N. R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.10.2393 · Cited by 176 · cited 1×
“Galantamine has two distinct roles: a selective, reversible, and competitive AChE inhibitor, as well as a modulator of the nicotinic ACh receptor [52].”
BackgroundChemical warfare agents: Toxicology and treatment
(1997) · General Pharmacology: The Vascular System · doi:10.1016/s0306-3623(97)89718-2 · Cited by 162
Xie, S.-S., Wang, X.-B., Li, J.-Y., Yang, L., & Kong, L.-Y. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.051 · Cited by 159 · cited 1×
“based on enzymes derived from different species (Figure 19) [104].”
BackgroundNovel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease
Romero, A., Cacabelos, R., Oset-Gasque, M. J., Samadi, A., & Marco-Contelles, J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.017 · Cited by 158
Acetylcholinesterase inhibitors: a patent review (2008 – present)
Pohanka, M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.701620 · Cited by 158
Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis
Pagano, G., Rengo, G., Pasqualetti, G., Femminella, G. D., Monzani, F., Ferrara, N., & Tagliati, M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308764 · Cited by 157 · cited 1×
“mors, rigidity, and postural instability; about 20% of patients will also develop dementia after 20 years [27].”
BackgroundCalcium channel blockers and dementia
Nimmrich, V, & Eckert, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12240 · Cited by 155 · cited 1×
“The overload of neuronal calcium levels could cause neuronal death and eventually leads to neurodegenerative disorders such as vascular dementia [95].”
BackgroundDesign, Synthesis, and Biological Evaluation of Conformationally Restricted Rivastigmine Analogues
Bolognesi, M. L., Bartolini, M., Cavalli, A., Andrisano, V., Rosini, M., Minarini, A., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049782n · Cited by 147 · cited 1×
“A recent study led by Bolognesi and coworkers has revealed a series of conformationally restricted rivastigmine analogs, such as compound 6, that have stronger in vitro anti-ChE activity than rivastigmine (Figure 9) [66].”
BackgroundPharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer??s Disease
Imbimbo, B. P. (2001) · CNS Drugs · doi:10.2165/00023210-200115050-00004 · Cited by 138 · cited 1×
“ever, occur when there is high fluctuation in the degree and duration of ChE inhibition [62].”
BackgroundMarco, J. L., Leon, R. M., Ríos, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodríguez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 137 · cited 1×
“[100] Compound 28, a truncated derivative of compound 27, showed near fourfold reduction of AChE inhibition while”
BackgroundChen, Y., Sun, J., Fang, L., Liu, M., Peng, S., Liao, H., Lehmann, J., & Zhang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300106z · Cited by 134 · cited 1×
“During their initial study of ferulic acid-based trihybrids, they found compound 30 with comparable sub-nanomolar inhibitory activities of both eeAChE and bovine BChE as compared to tacrine (Figure 18) [102].”
BackgroundInterventions for improving medical students' interpersonal communication in medical consultations
Gilligan, C., James, E. L., Snow, P., Outram, S., Ward, B. M., Powell, M., Lonsdale, C., Cushing, A. M., Silverman, J., Regan, T., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012418 · Cited by 124
Keri, R. S., Quintanova, C., Marques, S. M., Esteves, A. R., Cardoso, S. M., & Santos, M. A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.028 · Cited by 122
Poly(ADP-ribose) Polymerase-1 in Amyloid Beta Toxicity and Alzheimer's Disease
Strosznajder, J. B., Czapski, G. A., Adamczyk, A., & Strosznajder, R. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8258-9 · Cited by 115
Hamulakova, S., Janovec, L., Hrabinova, M., Spilovska, K., Korabecny, J., Kristian, P., Kuca, K., & Imrich, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008648 · Cited by 110 · cited 1×
“reported another series of tacrine–coumarin hybrids, in which they switched the connectivity of coumarin to C4-linkage and changed the linker to acyclic amide [105].”
BackgroundMultiple biological functions and pharmacological effects of lycorine
Cao, Z., Yang, P., & Zhou, Q. (2013) · Science China Chemistry · doi:10.1007/s11426-013-4967-9 · Cited by 108 · cited 1×
“Lycorine is another natural product that has a number of biological activities including anticancer, antivirus, and antiinflammatory properties [132].”
BackgroundBranduardi, D., Gervasio, F. L., Cavalli, A., Recanatini, M., & Parrinello, M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0512780 · Cited by 106 · cited 2×
“amyloid plaques, which in turn increases the expression of AChE [16,23].”
BackgroundChao, X., He, X., Yang, Y., Zhou, X., Jin, M., Liu, S., Cheng, Z., Liu, P., Wang, Y., Yu, J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.036 · Cited by 102 · cited 1×
“similar collection of analogs and found that there were no significant differences in both anti-AChE and anti-amyloid aggregation activities, as well as the free radical scavenging capacity [85].”
BackgroundLi, S., Wang, X., Xie, S., Jiang, N., Wang, K. D. G., Yao, H., Sun, H., & Kong, L. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.024 · Cited by 102 · cited 1×
“, published another series of tacrine–flavonoid hybrids using a similar approach and linker to study the substitution effect of flavonoid for the inhibition of AChE and Aβ aggregation (Figure 19) [106].”
BackgroundA critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
S. Schneider, L. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.2/lschneider · Cited by 97 · cited 1×
“Patients treated with AChE inhibitors also do not experience a complete reversal of the symptoms, but many do experience a slowed progression of symptoms for a period of time [24].”
BackgroundLi, S.-Y., Jiang, N., Xie, S.-S., Wang, K. D. G., Wang, X.-B., & Kong, L.-Y. (2014) · Org. Biomol. Chem. · doi:10.1039/c3ob42010h · Cited by 93
Chaudhaery, S. S., Roy, K. K., Shakya, N., Saxena, G., Sammi, S. R., Nazir, A., Nath, C., & Saxena, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100573q · Cited by 92
Wang, Y., Wang, H., & Chen, H. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094820 · Cited by 91 · cited 1×
“reviews on MTDLs in AD treatment have been well documented by Malawska’s group, as well as Wang and Chen’s group covering reports from early 2000 to 2014 [72,73].”
MethodSelf-citationTissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA
Jbilo, O., Bartels, C. F., Chatonnet, A., et al. (1994) · Toxicon · doi:10.1016/0041-0101(94)90416-2 · Cited by 87 · cited 1×
“AChE is most commonly found in skeletal muscles and the brain while BChE is found in abundance in the liver [5].”
BackgroundThe Adhesion Function on Acetylcholinesterase Is Located at the Peripheral Anionic Site
Johnson, G., & Moore, S. W. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0705 · Cited by 87 · cited 1×
“and the deposition of β-amyloid in Alzheimer’s disease (AD) [4].”
BackgroundLan, J., Xie, S., Li, S., Pan, L.-F., Wang, X., & Kong, L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.08.035 · Cited by 85
de los Ríos, C., Egea, J., Marco-Contelles, J., León, R., Samadi, A., Iriepa, I., Moraleda, I., Gálvez, E., García, A. G., López, M. G., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901902w · Cited by 77 · cited 1×
“not able to displace propidium iodide from PAS at 1 to 10 μM [101]; thus, compound 26 and the related analogs may not be considered as MTDLs for the ability to interact with both catalytic site and PAS of AChE.”
BackgroundKožurková, M., Hamuľaková, S., Gažová, Z., Paulíková, H., & Kristián, P. (2011) · Pharmaceuticals · doi:10.3390/ph4020382 · Cited by 75
Huang, W., Tang, L., Shi, Y., Huang, S., Xu, L., Sheng, R., Wu, P., Li, J. X., Zhou, N., & Hu, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.061 · Cited by 75
Katz, F. S., Pecic, S., Tran, T. H., Trakht, I. N., Schneider, L., Zhu, Z., Ton‐That, L., Luzac, M., Zlatanic, V., Damera, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500348 · Cited by 70 · cited 1×
“[153] provides some extremely interesting functional group SAR and crystal structural data supporting a unique mechanism of AChE reactivation.”
BackgroundMcNulty, J., Nair, J. J., Little, J. R. L., Brennan, J. D., & Bastida, J. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.130 · Cited by 70 · cited 1×
“, the parent molecule lycorine has been shown to have poor inhibitory activity in eeAChE [133].”
BackgroundSpuch, C., Antequera, D., Fernández‐Bachiller, M. I., Rodríguez-Franco, M. I., & Carro, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9121-2 · Cited by 69
Li, Y., Peng, P., Tang, L., Hu, Y., Hu, Y., & Sheng, R. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.009 · Cited by 61
A robust and scalable synthesis of the potent neuroprotective agent (−)-huperzine A
Tun, M. K. M., Wüstmann, D.-J., & Herzon, S. B. (2011) · Chemical Science · doi:10.1039/c1sc00455g · Cited by 59 · cited 1×
“Herzon’s group at Yale University has developed a highly practical and scalable route to prepare huperzine A in a costeffective fashion [58], which warrant the production and”
BackgroundSilva, D., Chioua, M., Samadi, A., Agostinho, P. M., Garção, P., Lajarín-Cuesta, R., Ríos, C. D. L., Iriepa, I., Moraleda, I., González‐Lafuente, L., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300178k · Cited by 58 · cited 2×
“In addition, the orientation and conformation of ACh is greatly influenced by the binding interaction toward the peripheral anionic site (PAS) that is comprised series of aromatic amino acid residues such as tyrosine (Y337 and Y130), phenylalanine (F338), and tryptophan (W86) [12].”
BackgroundLai, D.-H., Yang, Z., Xue, W., Sheng, J., Shi, Y., & Yao, X. (2013) · Fitoterapia · doi:10.1016/j.fitote.2013.06.010 · Cited by 54
Kochi, A., Eckroat, T. J., Green, K. D., Mayhoub, A. S., Lim, M. H., & Garneau‐Tsodikova, S. (2013) · Chemical Science · doi:10.1039/c3sc51902c · Cited by 51 · cited 1×
“prepared a tacrine–pyridinyl-containing hybrid 25 and found a similar anti-AChE activity as compared to tacrine [94].”
Myasthenia Gravis with Anti-Acetylcholine Receptor Antibodies
Meriggioli, M. N. (2009) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000212371 · Cited by 50
Mini review on blood–brain barrier penetration of pyridinium aldoximes
Kalász, H., Nurulain, S. M., Veress, G., Antus, S., Darvas, F., Adeghate, E. A., Adem, A., Hashemi, F., & Tekes, K. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.3048 · Cited by 47 · cited 1×
“fasciculation followed by flaccid paralysis [34].”
Dinamarca, M. C., Arrázola, M. S., Toledo, E. M., Cerpa, W. F., Hancke, J. L., & Inestrosa, N. C. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.026 · Cited by 46 · cited 1×
“A promising solution was found in APP transgenic mice, where spatial memory impairment was improved upon releasing AChE from the AChE–amyloid complexes through treatment with hyperforin [45].”
BackgroundLefèvre, G. Y., Pommier, F., Sedek, G., Allison, M. J., Huang, H. A., Kiese, B., Ho, Y., & Appel‐Dingemanse, S. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312154 · Cited by 45 · cited 1×
“the rapid fluctuation of ChE inhibition [63].”
Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS
Perioli, L., Ambrogi, V., Bernardini, C., Grandolini, G., Ricci, M., Giovagnoli, S., & Rossi, C. R. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.05.006 · Cited by 45 · cited 1×
“The lipophilic vector is labile and could be selectively removed under NADH redox conditions [112].”
BackgroundSamadi, A., Revenga, M. D. L. F., Pérez, C., Iriepa, I., Moraleda, I., Rodríguez-Franco, M. I., & Marco, J. L. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.06.021 · Cited by 40 · cited 1×
“(S203) which are members of the catalytic triad that are responsible for the hydrolysis of ACh [7].”
BackgroundDesign and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer’s disease
Hui, A., Chen, Y., Zhu, S.-J., Gan, C., Pan, J., & Zhou, A. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-0931-2 · Cited by 39
Roy, K. K., Tota, S., Tripathi, T., Chander, S., Nath, C., & Saxena, A. K. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.005 · Cited by 35 · cited 1×
“interaction at the catalytic site of AChE [69].”
BackgroundBartolucci, C., Stojan, J., Yu, Q., Greig, N. H., & Lamba, D. (2012) · Biochemical Journal · doi:10.1042/bj20111675 · Cited by 31
Discovering New Acetylcholinesterase Inhibitors by Mining the Buzhongyiqi Decoction Recipe Data
Cui, L., Wang, Y., Liu, Z., Chen, H., Wang, H., Zhou, X., & Xu, J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00449 · Cited by 29 · cited 1×
“In work done by Xu and coworkers, a new scaffold was derived from a natural product found in a traditional Chinese medicine for Myasthenia gravis called Buzhongiqi decoction (BD) [120].”
BackgroundSelf-citationChen, Y., Sun, J., Huang, Z., Liao, H., Peng, S., Lehmann, J., & Zhang, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.005 · Cited by 25 · cited 1×
“in addition to AChE inhibition on series of tacrine–flurbiprofen–nitric oxide trihybrid analogs [103].”
BackgroundWang, Y., Wan, Q.-L., Gu, C.-D., Luo, H., & Long, C. (2012) · Chemistry Central Journal · doi:10.1186/1752-153x-6-96 · Cited by 25
Loganathan, C., Chinnadurai, R. K., Basha, H. M., Ponne, S., & Boopathy, R. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24267 · Cited by 10
Goll, Y., Bekenstein, U., Barbash, S., Greenberg, D., Zangen, R., Shoham, S., & Soreq, H. (2013) · Neurodegenerative Diseases · doi:10.1159/000353689 · Cited by 8
Decker, M. W. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.6.733 · Cited by 3
Cited by
Yadav, Y. C., Singh, A., Kannaujia, S. K., & Yadav, R. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2022.100191 · Cited by 13
Metadata
- Authors
- McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & Valdez, M. C.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2017-01-17
- Volume
- 27
- Issue
- 4
- Pages
- 455-476
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2561776958
- Cited by
- 163
- References
- 94
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.